Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities.

摘要: The last 12 months have seen the beginning of a new era in treatment options available for patients with metastatic cutaneous melanoma, disease previously characterised by its poor prognosis and limited options. Two mechanistically diverse agents now demonstrated an overall survival benefit different patient subgroups further clinical trials are ongoing emerging single novel combinations. first agent to demonstrate was CTLA-4 antibody, ipilimumab, illustrating importance immune system immunomodulation melanoma tumorigenesis. second group show were selective BRAF inhibitors, vemurafenib GSK2118436, who V600 mutation positive. In addition, same mutant population, MEK inhibitors also promising results currently under investigation later stage trials. Although just passing through arena, their use will rapidly become more widespread. Along significant benefits, there unique adverse events related these agents. majority mild can be managed supportive treatment, some toxicities require special management strategies. We outline up-to-date development guidelines as well inhibitors.